20 April 2026
Latham & Watkins Advises on Allogene Therapeutics’ US$200.4 Million Public Offering of Common Stock
Advising firms
Deal team
14 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Shayne Kennedy Lead | Latham & Watkins LLP | Partner | corporate | Orange County/Bay Area |
| Greg Van Buiten | Latham & Watkins LLP | Associate | corporate | Not stated |
| Kennedy Holmes | Latham & Watkins LLP | Associate | corporate | Not stated |
| Tony Noh | Latham & Watkins LLP | Associate | corporate | Not stated |
| Chad Jennings | Latham & Watkins LLP | Counsel | FDA matters | Washington, D.C. |
| Evan Miller | Latham & Watkins LLP | Associate | FDA matters | Not stated |
| Betty Pang | Latham & Watkins LLP | Partner | healthcare matters | Bay Area |
| Darryl Steensma | Latham & Watkins LLP | Counsel | intellectual property matters | San Diego |
| Kristina Funahashi | Latham & Watkins LLP | Associate | intellectual property matters | Not stated |
| Dylan O'Connor | Latham & Watkins LLP | Associate | intellectual property matters | Not stated |
| Heather Deixler | Latham & Watkins LLP | Partner | data privacy matters | Bay Area |
| Chad Leiper | Latham & Watkins LLP | Associate | data privacy matters | Not stated |
| Grace Lee | Latham & Watkins LLP | Partner | tax matters | Bay Area |
| Tessa Young | Latham & Watkins LLP | Associate | tax matters | Not stated |
Stated terms
- Stated value
- USD 200m (US$200.4 million)
- What the figure measures
- Issue size
- Client
- Latham & Watkins LLPUnderwriters
- Counterparties
- Allogene Therapeutics, Inc. (Issuer)